Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 6/20 | 0.47 |
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | CTSB | P07858 | 4/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26230797 | 0.89 | ALB (0.55) | CTSLCTSSCTSB | |
| SCHEMBL25837527 | 0.87 | CTSL (0.62) | TAS1R3TAS1R1CTSLCTSSCTSB | |
| SCHEMBL30001307 | 0.83 | TAS1R3 (0.53) | TAS1R3TAS1R1CTSLCTSSCTSB | |
| SCHEMBL25244521 | 0.77 | MEN1 (0.61) | TAS1R3TAS1R1CTSLCTSSCTSB | |
| SCHEMBL25288556 | 0.77 | MEN1 (0.61) | TAS1R3TAS1R1CTSLCTSSCTSB | |
| SCHEMBL24019963 | 0.76 | MEN1 (0.55) | TAS1R3TAS1R1 | |
| SCHEMBL25287270 | 0.73 | TAS1R3 (0.70) | TAS1R3TAS1R1CTSLCTSS | |
| SCHEMBL25244832 | 0.73 | TAS1R3 (0.70) | TAS1R3TAS1R1CTSLCTSS | |
| SCHEMBL24029390 | 0.73 | MEN1 (0.62) | TAS1R3TAS1R1CTSLCTSSCTSB | |
| SCHEMBL30001311 | 0.73 | CTSL (0.68) | CTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11753373-B2 | Protease inhibitors as antivirals | ACEA Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230026438-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. | 2023-01-26 | — | — | US | disclosed |
| WO-2022256434-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026438-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | TAS1R3 1588/4885TAS1R1 1625/4885CTSL 4/4885 |
| US-11753373-B2 | Protease inhibitors as antivirals | ACE, ACE2, TMPRSS15 | TAS1R3 1588/4885TAS1R1 1625/4885CTSL 4/4885 |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | TAS1R3 1588/4885TAS1R1 1625/4885CTSL 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.